Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Point-Of-Care HbA1c Analyzer Enhanced

By LabMedica International staff writers
Posted on 29 Mar 2011
A point-of-care (POC) immunoassay analyzer for diabetes management provides enhanced operator management and connectivity capabilities to meet the growing demands in POC testing for improved compliance management and data capture into patient records.

The DCA Vantage Analyzer ensures that all analyzers are running the same quality control regimen required by their institution and that only authorized operators are running the devices according to their specified access level.

The operator management capability has been expanded to support up to 1,000 operators, each with their unique access level as defined by their supervisor. More...
Another enhancement to the analyzer is the ability to display, print, and transmit the HbA1c reference ranges with the patient results, aiding in improved results interpretation.

POC managers are demanding better connectivity between their POC analyzers and the associated healthcare organization so that test results can be automatically transmitted to the laboratory and hospital information systems, and eventually to the patient's electronic medical record.

Siemens Healthcare Diagnostics (Erlangen, Germany) launched the DCA Vantage Analyzer with Version 3.0 software. It has the capacity to manage a larger number of operators while providing the required security access modes to prevent unauthorized use. In addition, the analyzer is one of the first hemoglobin A1c (HbA1c) POC analyzers in the industry to include the POCT1-A2 communication protocol. Use of this standard interface simplifies the connection to POC data management systems, enabling results to be automatically transmitted to the patient electronic medical record.

"We are focused on providing our customers with a trusted, clinically proven, point-of-care analyzer to better manage diabetes patients at the time of visit," said Dr. David Stein, CEO, POC business unit, Siemens Healthcare Diagnostics. "At the same time, we are continually looking at ways to enhance our products to meet the changing needs of our customers. These newly added features are important to point-of-care managers who are responsible for tests conducted at remote sites with multiple operators and devices in order to drive testing compliance."

Related Links:

Siemens Healthcare Diagnostics



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.